Apnimed

Bed floating on a cloud with the full moon behind it

Apnimed's sleep apnea star goes 2 for 2 in phase 3

Patients receiving AD109 had a 46.8% reduction in a measure of sleep apnea severity, highlighting the asset's potential to treat the common condition.

Darren Incorvaia Jul 23, 2025 6:00am

Apnimed eyes FDA sleep apnea submission after positive results

May 19, 2025 6:00am

Pfizer's migraine market chief joins Apnimed—Chutes & Ladders

Jan 26, 2024 9:30am

Wall Street stock exchange new York shares market

Two biotechs go public while Apnimed bides its time

Oct 2, 2023 11:02am

graphic of a bed illuminated atop a cloud

Apnimed nails study of sleep apnea med, tees up phase 3 test

May 22, 2023 10:45am

Apnimed secures $62.5M to push sleep disorder drug development

May 4, 2022 10:22am